{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:30:15Z","timestamp":1791819015821,"version":"4.3.4"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000200","name":"USAID","doi-asserted-by":"publisher","award":["7200GH21IO00005"],"award-info":[{"award-number":["7200GH21IO00005"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Glob. Womens Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Contraceptives play a crucial role in women's reproductive health, their hormonal components may be linked to cancer risks, specifically breast, and gynecological cancers. Given the high usage rates of hormonal contraceptives, it is vital to systematically evaluate their potential impact on cancer outcomes, especially among women with a family history of gynecological cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aims to evaluate the evidence on the association between modern contraceptive use and the risk of breast and reproductive cancers (ovarian, endometrial, and cervical cancer) among women of reproductive age, to inform healthcare providers, women, and program managers about cancer outcomes related to contraceptive use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted according to PRISMA guidelines. Searches were performed in databases such as CINAHL, OVID Medline, EMBASE, and more from inception to February 2022. Eligible studies included randomized controlled trials, cohort studies, and case-control studies that compared cancer outcomes between contraceptive users and non-users. Data extraction, quality assessment, and meta-analyses were conducted following predefined protocols. Subgroup and sensitivity analyses examined variations in contraceptive methods, doses, and duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 51 studies were included, comprising 2 RCTs and 49 observational studies. The review identified a significant reduction in ovarian and endometrial cancer incidence among contraceptive users. Hormonal contraceptive users had a 36% lower risk of ovarian cancer (RR 0.64, 95% CI 0.60\u20130.68), with specific reductions seen in combined oral contraceptive users (RR 0.62, 95% CI 0.57\u20130.68) and hormonal IUD users (RR 0.68, 95% CI 0.48\u20130.96). The rate ratio of cervical cancer was higher among non- users compared to hormonal contraceptive users when we pooled the results (1.28, 95% CI 1.21, 1.35). No significant association was found between contraceptive use and breast cancer risk among healthy women (RR 1.00, 95% CI 0.94\u20131.06). However, BRCA1\/2 mutation carriers using oral contraceptives showed a heightened risk of breast cancer (HR 1.39, 95% CI 1.15\u20131.67).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This systematic review highlights the protective effects of modern contraceptives against ovarian and endometrial cancers while identifying an increased risk of cervical. No significant breast cancer risk was found for healthy women, but BRCA1\/2 mutation carriers faced increased risks. These findings underscore the need for personalized contraceptive counselling that considers cancer risk factors. Further research is needed to explore contraceptive impacts across different genetic profiles and dosing regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>\n                      , Prospero (CRD42022332647).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgwh.2024.1487820","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T06:45:47Z","timestamp":1731480347000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessing the impact of contraceptive use on reproductive cancer risk among women of reproductive age\u2014a systematic review"],"prefix":"10.3389","volume":"5","author":[{"given":"Shayesteh","family":"Jahanfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Mortazavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Lapidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Cu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Al Abosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathyrn","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Camilo","family":"Becerra-Mateus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Steinfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Bohang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Andrenacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Badawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moazzam","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"B1","article-title":"Contraceptive Use by Method 2019: Data Booklet (ST\/ESA\/SER.A\/435)","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/med.20131","article-title":"Estrogen and its receptors in cancer","volume":"28","author":"Chen","year":"2008","journal-title":"Med Res Rev"},{"key":"B3","article-title":"Estimated Number of New Cases in 2020, World, Females, All Ages","year":"2020"},{"key":"B4","article-title":"US Medical Eligibility Criteria for Contraceptive Use, 2016 (US MEC)","year":""},{"key":"B5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaoncol.2017.4942","article-title":"Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers","volume":"4","author":"Michels","year":"2018","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10654-015-0030-9","article-title":"An epidemiological model for prediction of endometrial cancer risk in Europe","volume":"31","author":"H\u00fcsing","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/ijc.11474","article-title":"Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial","volume":"107","author":"Hogewoning","year":"2003","journal-title":"Int J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"381.e1","DOI":"10.1016\/j.ajog.2018.07.024","article-title":"While women await surgery for type I endometrial cancer, depot medroxyprogesterone acetate reduces tumor glandular cellularity","volume":"219","author":"Fiascone","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/oxfordjournals.aje.a116419","article-title":"The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer","volume":"83","author":"Gross","year":"1994","journal-title":"Obstet Gynecol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1067\/mob.2002.118657","article-title":"Family history of cancer, oral contraceptive use, and ovarian cancer risk","volume":"186","author":"Walker","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejca.2019.10.009","article-title":"Oral contraceptive and intrauterine device use and the risk of cervical intraepithelial neoplasia grade III or worse: a population-based study","volume":"124","author":"Loopik","year":"2020","journal-title":"Eur J Cancer Oxf Engl"},{"key":"B12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/oxfordjournals.aje.a009112","article-title":"Heath, tubal ligation and fatal ovarian cancer in a large prospective cohort study","volume":"145","author":"Miracle-McMahill","year":"1997","journal-title":"Am J Epidemiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1158\/1055-9965.EPI-17-0722","article-title":"Exogenous hormone use and endometrial cancer in U.S. Black women","volume":"27","author":"Sponholtz","year":"2018","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1158\/1055-9965.EPI-09-0156","article-title":"Influence of reproductive factors on mortality after epithelial ovarian cancer diagnosis","volume":"18","author":"Robbins","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B15","first-page":"933","article-title":"Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The world health organization collaborative study of neoplasia and steroid contraceptives","volume":"5","author":"Rosenblatt","year":"1996","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14034940510032239","article-title":"Use of oral contraceptives and mortality during 14 years\u2019 follow-up of Norwegian women","volume":"34","author":"Graff-Iversen","year":"2006","journal-title":"Scand J Public Health"},{"key":"B17","doi-asserted-by":"publisher","first-page":"447.e1","DOI":"10.1016\/j.ajog.2007.01.022","article-title":"Tubal sterilization, all-cause death, and cancer among women in the United Kingdom: evidence from the royal college of general practitioners\u2019 oral contraception study","volume":"196","author":"Iversen","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12916-015-0484-3","article-title":"Reproductive factors and risk of mortality in the European prospective investigation into cancer and nutrition; a cohort study","volume":"13","author":"Merritt","year":"2015","journal-title":"BMC Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10552-017-0876-0","article-title":"A prospective cohort study of oral contraceptive use and ovarian cancer among women in the United States born from 1947 to 1964","volume":"28","author":"Shafrir","year":"2017","journal-title":"Cancer Causes Control"},{"key":"B20","first-page":"4729","article-title":"Oral contraceptives are not an independent risk factor for cervical intraepithelial neoplasia or high-risk human papillomavirus infections","volume":"26","author":"Syrj\u00e4nen","year":"2006","journal-title":"Anticancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.contraception.2013.12.011","article-title":"Injectable and oral contraception and the incidence and progression of cervical disease in HIV-infected women in South Africa","volume":"89","author":"Westreich","year":"2014","journal-title":"Contraception"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/bjc.2011.371","article-title":"Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European prospective investigation into cancer and nutrition","volume":"105","author":"Tsilidis","year":"2011","journal-title":"Br J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1001\/jama.284.14.1791","article-title":"Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer","volume":"284","author":"Grabrick","year":"2000","journal-title":"JAMA"},{"key":"B24","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3","author":"Higgins","year":"2022"},{"key":"B25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.midw.2005.05.004","article-title":"Appraising the quality of qualitative research","volume":"22","author":"Walsh","year":"2006","journal-title":"Midwifery"},{"key":"B27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1158\/0008-5472.CAN-20-2476","article-title":"Time-Dependent effects of oral contraceptive use on breast, ovarian, and endometrial cancers","volume":"81","author":"Karlsson","year":"2021","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s10552-013-0296-8","article-title":"Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer","volume":"24","author":"Faber","year":"2013","journal-title":"Cancer Causes Control"},{"key":"B30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1158\/1538-7445.AM2021-878","article-title":"Contraceptive use and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"81","author":"Xia","year":"2021","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.7314\/APJCP.2014.15.14.5517","article-title":"Risk of cancer with combined oral contraceptive use among Iranian women","volume":"15","author":"Vaisy","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/bjc.1996.247","article-title":"Oral contraceptives and cervical cancer-further findings from the Oxford family planning association contraceptive study","volume":"73","author":"Zondervan","year":"1996","journal-title":"Br J Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0140-6736(88)90869-0","article-title":"Oral contraceptive use and malignancies of the genital tract. Results from the royal college of general practitioners\u2019 oral contraception study","volume":"2","author":"Beral","year":"1988","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/1097-0142(19950715)76:2%3C284::aid-cncr2820760219%3E3.0.co;2-5","article-title":"A prospective study of reproductive factors and risk of epithelial ovarian cancer","volume":"76","author":"Hankinson","year":"1995","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"580.e1","DOI":"10.1016\/j.ajog.2017.02.002","article-title":"Lifetime cancer risk and combined oral contraceptives: the royal college of general Practitioners\u2019 oral contraception study","volume":"216","author":"Iversen","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"k3609","DOI":"10.1136\/bmj.k3609","article-title":"Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study","volume":"362","author":"Iversen","year":"2018","journal-title":"Br Med J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.contraception.2020.06.008","article-title":"Contemporary hormonal contraception and risk of endometrial cancer in women younger than age 50: a retrospective cohort study of danish women","volume":"102","author":"Iversen","year":"2020","journal-title":"Contraception"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33585","article-title":"Contemporary hormonal contraception and cervical cancer in women of reproductive age","author":"Iversen","year":"2021","journal-title":"Int J Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/sj.bjc.6601715","article-title":"Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish women\u2019s lifestyle and health cohort study","volume":"90","author":"Kumle","year":"2004","journal-title":"Br J Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10552-008-9213-y","article-title":"Oral contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai","volume":"20","author":"Rosenblatt","year":"2009","journal-title":"Cancer Causes Control"},{"key":"B41","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.contraception.2013.08.008","article-title":"Oral contraceptive use and cancer: final report from the Oxford-family planning association contraceptive study","volume":"88","author":"Vessey","year":"2013","journal-title":"Contraception"},{"key":"B42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.contraception.2010.04.006","article-title":"Factors affecting mortality in a large cohort study with special reference to oral contraceptive use","volume":"82","author":"Vessey","year":"2010","journal-title":"Contraception"},{"key":"B43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ygyno.2018.02.006","article-title":"Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC study","volume":"149","author":"Jareid","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.contraception.2007.03.004","article-title":"Monthly injectable contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai","volume":"76","author":"Rosenblatt","year":"2007","journal-title":"Contraception"},{"key":"B45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ebobgyn.2005.03.008","article-title":"Risk of invasive epithelial ovarian neoplasia declined with each year of hormonal contraceptive use","volume":"7","year":"2005","journal-title":"Evid-Based Obstet Gynecol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/aje\/kwm157","article-title":"Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk","volume":"166","author":"Tworoger","year":"2007","journal-title":"Am J Epidemiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1002\/ijc.24232","article-title":"Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006","volume":"124","author":"Dorjgochoo","year":"2009","journal-title":"Int J Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ijc.31287","article-title":"Association between tubal ligation and endometrial cancer risk: a Swedish population-based cohort study","volume":"143","author":"Falconer","year":"2018","journal-title":"Int J Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/IGC.0000000000000651","article-title":"Tubal ligation and risk of endometrial cancer: findings from the women\u2019s health initiative","volume":"26","author":"Winer","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.fertnstert.2014.03.041","article-title":"Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses\u2019 health studies","volume":"102","author":"Rice","year":"2014","journal-title":"Fertil Steril"},{"key":"B51","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/bmj.318.7176.96","article-title":"Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from royal college of general practitioners\u2019 oral contraception study","volume":"318","author":"Beral","year":"1999","journal-title":"Br Med J"},{"key":"B52","doi-asserted-by":"publisher","first-page":"821","DOI":"10.7326\/0003-4819-120-10-199405150-00002","article-title":"Oral contraceptive use and mortality during 12 years of follow-up: the Nurses\u2019 health study","volume":"120","author":"Colditz","year":"1994","journal-title":"Ann Intern Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"c927","DOI":"10.1136\/bmj.c927","article-title":"Mortality among contraceptive pill users: cohort evidence from royal college of general Practitioners\u2019 oral contraception study","volume":"340","author":"Hannaford","year":"2010","journal-title":"Br Med J"},{"key":"B54","doi-asserted-by":"publisher","first-page":"51.e1","DOI":"10.1016\/j.ajog.2021.01.014","article-title":"Epidemiological study of familial breast cancer, gene etude prospective sein ovaire sein, hereditary breast and ovarian cancer research group Netherlands, and international BRCA1\/2 carrier cohort study. Oral contraceptive use and ovarian cancer risk for BRCA1\/2 mutation carriers: an international cohort study","volume":"225","author":"Schrijver","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1200\/JCO.2007.11.1179","article-title":"Oral contraceptives and breast cancer risk in the international BRCA1\/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS collaborating group","volume":"25","author":"Brohet","year":"2007","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"pky023","DOI":"10.1093\/jncics\/pky023","article-title":"Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study","volume":"2","author":"Schrijver","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"B57","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/sj.bjc.6603260","article-title":"Oral contraceptive use and cancer. Findings in a large cohort study, 1968\u20132004","volume":"95","author":"Vessey","year":"2006","journal-title":"Br J Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1158\/1055-9965.EPI-08-0546","article-title":"Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the international BRCA1\/2 carrier cohort study","volume":"18","author":"Antoniou","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B59","doi-asserted-by":"publisher","first-page":"g6356","DOI":"10.1136\/bmj.g6356","article-title":"Oral contraceptive use and mortality after 36 years of follow-up in the nurses\u2019 health study: prospective cohort study","volume":"349","author":"Charlton","year":"2014","journal-title":"Br Med J"},{"key":"B60","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s10654-020-00705-5","article-title":"Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947\u20131964: the nurses\u2019 health study II, a prospective cohort study","volume":"36","author":"Burchardt","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/AOG.0b013e318291c235","article-title":"Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis","volume":"122","author":"Havrilesky","year":"2013","journal-title":"Obstet Gynecol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.gofs.2018.10.010","article-title":"[Contraception and cancer: cNGOF contraception guidelines]","volume":"46","author":"Pragout","year":"2018","journal-title":"Gynecol Obstet Fertil Senol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejogrb.2020.02.014","article-title":"Oral contraceptives use and risk of cervical cancer-a systematic review & meta-analysis","volume":"247","author":"Asthana","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/aogs.13817","article-title":"Levonorgestrel-releasing intrauterine system and breast cancer risk: a systematic review and meta-analysis","volume":"99","author":"Conz","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B65","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00404-020-05458-w","article-title":"Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review","volume":"301","author":"Huber","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"B66","article-title":"MEC for Contraceptive Use","year":""}],"container-title":["Frontiers in Global Women's Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgwh.2024.1487820\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T12:40:48Z","timestamp":1735216848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgwh.2024.1487820\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":66,"alternative-id":["10.3389\/fgwh.2024.1487820"],"URL":"https:\/\/doi.org\/10.3389\/fgwh.2024.1487820","relation":{},"ISSN":["2673-5059"],"issn-type":[{"value":"2673-5059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"article-number":"1487820"}}